2023 was a tricky yr for the biopharma field, with many businesses downsizing and restructuring their workforces to remain afloat. You can find signs of recovery, as mergers and acquisitions picked up through the pharmaceutical and daily life sciences business from the latter Portion of 2023 and also have continued https://sites.google.com/view/bio-sites/blog